T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer
- 1 June 2002
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 9 (12) , 786-792
- https://doi.org/10.1038/sj.gt.3301687
Abstract
At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.Keywords
This publication has 14 references indexed in Scilit:
- Rejection of Disseminated Metastases of Colon Carcinoma by Synergism of IL-12 Gene Therapy and 4-1BB CostimulationMolecular Therapy, 2000
- Immunomodulatory Gene Therapy With Interleukin 12 and 4-1BB Ligand: Long- Term Remission of Liver Metastases in a Mouse ModelJNCI Journal of the National Cancer Institute, 2000
- Anti-tumor immunity induced by Interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cellsBreast Cancer Research and Treatment, 2000
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathwayEuropean Journal of Immunology, 1998
- Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumorsNature Medicine, 1997
- Methods for construction of adenovirus vectorsMolecular Biotechnology, 1995
- Molecular cloning of a ligand for the inducible T cell gene 4‐1BB: a member of an emerging family of cytokines with homology to tumor necrosis factorEuropean Journal of Immunology, 1993
- CD4-POSITIVE AND B LYMPHOCYTES IN TRANSPLANTATION IMMUNITYTransplantation, 1993
- Regulation of human cytolytic lymphocyte responses by interleukin-12Cellular Immunology, 1992